MSS/ MSI-L colorectal cancer
Conditions
Interventions
Experimental group:Tislelizumab With Fruquintinib, Metronidazole
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. No gender limit, age >= 18 years old and = 1.5 × 10^9/L, platelet >= 100 × 10^9/L Liver function: ALT and AST = 30g/L Renal function: serum creatinine = 50 mL/min (calculated according to Cockcroft Gault formula). 7. Those who voluntarily participate in the trial and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Chronic intestinal diseases (such as Crohn's disease, ulcerative colitis, etc.), infectious intestinal diseases during the screening period, and intestinal obstruction during the screening period; 3. Subjects with poor control of hypertension (systolic blood pressure>150 mmHg and/or diastolic blood pressure>100 mmHg) and a history of hypertensive crisis or hypertensive brain disease; 4. Severe liver and kidney function or heart dysfunction; 5. Patients who use antibiotics for more than 5 days within one month prior to immunotherapy; 6. Patients with known brain or meningeal metastases, regardless of whether they have received treatment, are not eligible for inclusion in this trial. 7. Individuals with contraindications to the use of metronidazole medication; 8. Those who are unwilling to participate in the trial or sign informed consent forms; 9. The researchers believe that there are any situations that are not suitable for selection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free-Survival;Overall Survival;Disease Control Rate;Duration of Response; | — |
Countries
China
Contacts
Public ContactFang Jingyuan
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed